Dietrich John Pauls - 28 Jul 2021 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role: President and CEO, Director
Signature: /s/ Amy Culbert, attorney-in-fact
Issuer symbol: DMAC
Transactions as of: 28 Jul 2021
Net transactions value: $0
Form type: 4
Filing time: 29 Jul 2021, 21:07:43 UTC
Next filing: 16 Aug 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	DMAC	Voting Common Shares, no par value per share						30,804	28 Jul 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DMAC	Stock Option (right to buy)	Award	$0	+175,000		$0.000000	175,000	28 Jul 2021	Common Shares	175,000	$5.00	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan.
F2	Vests in sixteen nearly equal quarterly installments over four years.